An open-label, multicohort, phase II study of Atezolizumab in advanced solid tumors

Phase 1

• Conditions: Patients with histologically documented advanced solid tumors thatmeet protocol-defined cohort specifications, have progressed followingat least one line of prior systemic anticancer therapy, or for which thereis no alternative therapy known to prolong survival.; MedDRA version: 20.0Level: PTClassification code 10062042Term: Lung neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 21.1Level: PTClassification code 10055108Term: Thymic cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 20.0Level: PTClassification code 10039491Term: SarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 20.1Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 21.1Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 20.0Level: PTClassification code 10043670Term: ThymomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 21.0Level: PTClassification code 10041823Term: Squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

• Registration Number: EUCTR2015-000269-30-PL
• Lead Sponsor: F. Hoffmann-La Roche Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-06-30
• Last Update Posted: 5 April 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 725

Inclusion Criteria

- Male or female, 18 years of age or older

- Histologically documented advanced (i.e. stages III or IV) solid
tumors that meet protocol-defined cohort specifications, with
progressive disease at study entry and at least one prior line of systemic
anticancer therapy or for which there is no alternative therapy known to
prolong survival.
- Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks or, in exceptional cases, 15 freshly cut and unstained slides, with an associated pathology report, for central testing. Measurable disease as defined by RECIST v1.1. or disease-specific
criteria for prostate cancer and malignant pleural mesothelioma
- Eastern Cooperative Oncology group (ECOG) Performance Status of 0
or 1
- Adequate hematologic and end organ function
- Negative serum pregnancy test result within 14 days prior to
initiation of study drug among women of child-bearing potential
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 545
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 180

Exclusion Criteria

- Malignancies other than disease under study within 5 years prior to
Cycle 1 Day 1, with the exception of those with a negligible risk of
metastasis or death
- Uncontrolled tumor-related pain
- Uncontrolled pleural effusion, pericardial effusion, or ascites
requiring recurrent drainage procedures
- Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring
continued use of bisphosphonate therapy or denosumab
- History of treated asymptomatic or symptomatic CNS metastasis or
presence of CNS metastases as determined by CT scan or MRI evaluation
during screening or at prior radiographic assessments
- Leptomeningeal disease
- Spinal cord compression not definitively treated with surgery and/or
radiation, or previously diagnosed and treated but not clinically stable
for = 2 weeks prior to Cycle 1, Day 1
- Any approved anticancer therapy, including chemotherapy, hormonal
therapy or radiotherapy, within 3 weeks prior to initiation of study
treatment, with certain exceptions
- Acute toxicities from previous therapy that have not resolved to
Grade = 1, except for alopecia
- Pregnant and lactating women
- Evidence of significant uncontrolled concomitant disease that could
affect compliance with the protocol or interpretation of results, including
significant liver disease
- Any other diseases, metabolic dysfunction, physical examination
finding or clinical laboratory finding giving reasonable suspicion of a
disease or condition that contraindicates the use of an investigational
drug or that may affect the interpretation of the results or render the
patient at high risk from treatment complication
- Significant cardiovascular disease within 3 months prior to Cycle 1, Day 1
- Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1
- Severe infections within 4 weeks prior to Cycle 1, Day 1
- Received oral or IV antibiotics within 2 weeks prior to Cycle 1, Day
- Active tuberculosis
- Positive test for HIV
- Patients with a positive hepatitis B surface antigen [HBsAg] test at
screening or hepatitis C
- Major surgical procedure within 28 days prior to Cycle 1, Day 1 or
anticipation of need for a major surgical procedure during the course of
the study
- History of autoimmune disease, except treated/stable autoimmune
hypothyroidism or controlled type 1 diabetes mellitus on a stable insulin
regimen. Patients with eczema, psoriasis, lichen simplex chronicus, or
vitiligo with dermatologic manifestations only are permitted provided
that they meet certain pre-specified conditions.
- History of severe allergic, anaphylactic, or other hypersensitivity
reactions to chimeric or humanized antibodies or fusion proteins
- Prior allogeneic bone marrow transplantation or prior solid organ
transplantation
- History of idiopathic pulmonary fibrosis, drug-induced pneumonitis,
organizing pneumonia, or evidence of active pneumonitis on screening
chest CT scan
- Administration of a live, attenuated vaccine within 4 weeks prior to
Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be
required during the study treatment or within 5 months after the last
dose of atezolizumab
- Prior treatment with CD137 agonists or immune checkpoint blockade
therapies, anti-PD1, or anti-PDL1 therapeutic antibodies
- Treatment with systemic immunostimulatory agents or with an
investigational agent within 4 weeks or five half-lives of the drug prior
to Cycle 1, Day 1
- Treatment with systemic corticosteroids or other systemic
immunosuppressive medicati

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified